Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $57.00. Th...
网页链接Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $57.00. Th...
网页链接
精彩评论